News

Sandoz and Beximco Pharmaceuticals Join the Medicines Patent Pool’s Growing Network of Generic Manufacturing Partners

On World AIDS Day, the organization releases new impact numbers noting progress of generic partners to deliver low-cost, high quality HIV medicines to developing countries

Geneva, 1 December 2016 - The Medicines Patent Pool (MPP) today announced the expansion of its network of generic manufacturers to include Sandoz and Beximco Pharmaceuticals Ltd. to help produce much needed hepatitis C treatments for developing countries. Both companies have signed sub-licensing agreements to manufacture Bristol-Myers Squibb′s (BMS) daclatasvir, a new direct-acting antiviral for hepatitis C that, when used in combination with other treatments, is proven to cure multiple genotypes of the HCV virus. The MPP signed a license and technology transfer agreement with BMS for the treatment in November, 2015.

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has received US Food and Drug Administration (FDA) approval for Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, following submission of an Abbreviated New Drug Application (ANDA) in June 2014. This is the second product from Beximco Pharma to be approved by the US FDA after Carvedilol, a prescription drug for treating hypertension, which was approved in July 2015.

Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”) becomes the first Bangladeshi pharmaceutical company to be approved by the U.S. Food and Drug Administration (US FDA) following a successful inspection of its oral solid dosage facility at Tongi, during January 19-22, 2015. The company says it has received the establishment inspection report (EIR) from the US drug regulatory authority stating that the audit is formally concluded. This is a major milestone for the company as well as for the entire industry as this is the first time a Bangladeshi company has received the prestigious FDA approval.

Beximco Pharmaceuticals Ltd (Beximco Pharma) is an emerging generic drug player committed to providing access to affordable medicines.

Follow Us